Psychiatric symptoms associated with L-asparaginase administration.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001215:Asparaginase / Q000009:adverse effects* / Q000627:therapeutic use; D001216:Asparagine / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D002908:Chronic Disease; D003221:Confusion / Q000139:chemically induced; D003244:Consciousness Disorders / Q000139:chemically induced; D003863:Depression / Q000139:chemically induced; D005260:Female; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D007275:Injections, Intravenous; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000096:biosynthesis; D011605:Psychoses, Substance-Induced / Q000209:etiology*; D013850:Thinking / Q000187:drug effects; D013997:Time Factors
D009419:Nerve Tissue Proteins; D001216:Asparagine; D001215:Asparaginase